U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment
On Tuesday, officials from the National Institute of Health (NIH) announced the initiation of a clinical trial in which patients in U.S. hospitals with confirmed COVID-19 infections will be given Gilead Sciences' (NASDAQ: GILD) drug remdesivir.
The first clinical trial participant was an American currently at the Nebraska Medical Center in Omaha, who had been quarantined with other infected passengers from the Diamond Princess cruise ship.
Image source: Getty Images.
Source Fool.com
